Lv1
40 积分 2026-06-03 加入
Phase I study of the oral GLP-1 receptor agonist DA-302168S: safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults
14天前
已完结
GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: a randomized, placebo-controlled, phase 1b/2a trial
14天前
已完结
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: a phase 2 randomized controlled trial
14天前
已完结
Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight (LIGHT 1): a randomized, double-blind, placebo-controlled, ascending-dose phase 2a trial
14天前
已完结
HDM1002 in Chinese Adults With Overweight/Obesity: a Randomized, Placebo-Controlled, Ascending-Dose Phase 1b Study
14天前
已完结
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial
15天前
已完结
Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease
1个月前
已完结
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial
1个月前
已完结
皖公网安备34019202002308
